接受桥接治疗的肝细胞癌患者延迟肝移植策略的评估:DELTA-HCC研究
法国2015年起对等待期接受切除或热消融的单发肝细胞癌患者采用延迟肝移植策略(DS),即推迟至复发再移植。DELTA-HCC研究纳入2015至2018年法国2,025例患者,比较六组结局,显示DS组移植前脱落概率显著低于其他组(13% vs 19%,p=0.0043),移植后5年生存率各组无差异,DS组为74%(p=0.22)。
要点
- DS组中位等待时间910天,移植前脱落概率13%,显著低于其他组的19%(p=0.0043)。
- T1组移植前脱落概率显著更高,为25.4%(p=0.05)。
- 多结节组移植后肝癌复发率显著更高,为19.6%(p=0.019)。
核心结论
- DELTA-HCC研究显示延迟肝移植策略(DS)对移植前和移植后患者结局均无负面影响,并有可能将器官重新分配给更急需肝移植的患者。
- 该策略可合理提出并继续实施。
- T1患者脱落风险意外偏高,似乎与基于MELD的分配规则对该亚组服务不足有关。
研究设计与样本
- 研究纳入2015至2018年法国国家肝移植数据库中登记的肝细胞癌患者,共识别2,025例。
- 患者分为六组:进入DS的单发肿瘤、未进入DS的单发肿瘤、多发肿瘤、无治愈性治疗、不可治疗的肝细胞癌或T1肿瘤。
- 采用Kaplan-Meier法估计移植前18个月内因死亡、病情过重无法移植或肿瘤进展的脱落风险,以及移植后5年肝癌复发率和移植后生存率,并进行组间比较。
主要发现
- DS组中位等待时间为910天。
- DS组移植前脱落概率显著低于其他组(13% vs 19%,p=0.0043)。
- T1组移植前脱落概率显著更高(25.4%,p=0.05)。
- 多结节组移植后肝癌复发率显著更高(19.6%,p=0.019)。
- 移植后5年生存率各组无差异,DS组为74%(p=0.22)。
临床怎么用
- 作者认为,延迟肝移植策略可合理提出并继续实施。
- 作者认为,该策略可考虑扩展至其他肝移植项目。
- 作者指出,T1患者脱落风险意外偏高,似乎与基于MELD的分配规则对该亚组服务不足有关,呼吁进一步审查和修订该亚组的分配规则。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: To maximize utility and prevent premature liver transplantation (LT), a delayed LT strategy (DS) was adopted in France in 2015 in patients listed for any single HCC treated with resection or thermal ablation during the waiting phase. The DS involves postponing LT until recurrence. The purpose of this study was to evaluate the DS to make sure that it did not hamper pre- and post-LT outcomes. METHODS: Patients listed for HCC in France between 2015 and 2018 were studied. After data extraction from the national LT database, 2,025 patients were identified and classified according to six groups: single tumor entering DS, single tumor not entering DS, multiple tumors, no curative treatment, untreatable HCC or T1 tumors. Kaplan-Meier estimates of the 18-month risk of dropout for death, too sick to be transplanted or tumor progression before LT, 5-year post-LT HCC recurrence and post-LT survival rates were compared. RESULTS: Median waiting-time in the DS group was 910 days. Pre-LT dropout probability was significantly lower in the DS group compared to other groups (13% vs. 19%, p = 0.0043) and significantly higher in the T1 group (25.4%, p = 0.05). Post-LT HCC recurrence rate in the multiple nodules group was significantly higher (19.6%, p = 0.019), while 5-year post-LT survival did not differ among groups and was 74% in the DS group (p = 0.22). CONCLUSION: The DELTA-HCC study shows that DS does not negatively impact either pre- nor post-LT patient outcomes, and has the potential to allow for redistribution of organs to patients in more urgent need of LT. It can reasonably be proposed and pursued. The unexpectedly high risk of dropout in T1 patients seems related to the MELD-based offering rules underserving this subgroup. IMPACTS AND IMPLICATIONS: To maximize utility and prevent premature liver transplantation (LT), a delayed LT strategy was adopted in France in 2015. It involves postponing LT until recurrence in patients listed for any single HCC curatively treated by surgical resection or thermal ablation. The DELTA-HCC study was conducted to evaluate this nationwide strategy. It shows in a European LT program that delayed strategy does not negatively impact pre- nor post-LT patient outcomes and is relevant to up to 20% of LT candidates; thus, it could potentially enable the redistribution of organs to patients in more urgent need of LT. Such a delayed strategy can reasonably be pursued and extended to other LT programs. Of note, an unexpectedly high risk of dropout in T1 patients, seemingly related to MELD-based offering rules which underserve these patients, calls for further scrutinization and revision of allocation rules in this subgroup.
引用
- Lamarque C, Segaux L, Bachellier P, et al. Evaluation of a delayed liver transplantation strategy for patients with HCC receiving bridging therapy: the DELTA-HCC study. J Hepatol. 2024. PMID: 38521171. doi:10.1016/j.jhep.2024.03.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。